A PHASE 3 RANDOMIZED OPEN-LABEL STUDY OF ADJUVANT PEMBROLIZUMAB WITH OR WITHOUT MK-2870 IN PARTICIPANTS WITH RESECTABLE STAGE II TO IIIB (N2) NSCLC NOT ACHIEVING PCR AFTER RECEIVING NEOADJUVANT PEMBROLIZUMAB WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY FOLLOWED BY SURGERY

Registry ID

MK-2870-019

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

MERCK CANADA INC

Start date

2025-03-31

Last update

2024-02-28

Conditions

• NON-SMALL CELL LUNG CANCER - CACHEXIA (NSCLC-C)

Related clinical trials

• ROSETTA LUNG-201: A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE 3 STUDY OF PUMITAMIG MONOTHERAPY COMPARED TO DURVALUMAB IN PARTICIPANTS WITH UNRESECTABLE STAGE III NSCLC WITHOUT PROGRESSION AFTER PLATINUM-BASED CONCURRENT CHEMORADIATION THERAPY
• A PHASE 2B/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
• A PHASE III, RANDOMISED, OPEN-LABEL, MULTICENTRE, GLOBAL STUDY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) IN COMBINATION WITH DURVALUMAB AND CARBOPLATIN VERSUS PEMBROLIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WITHOUT ACTIONABLE GENOMIC ALTERATIONS (AVANZAR)
• A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED MULTICENTER STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED LEVELS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD.

View on source registry